Comorbidity-related medical expenditures and health outcomes in cancer patients.
Abstract
1641 Background: Comorbidities are common among adults with cancer and necessitate effective medical management. However, research is scarce on how cancer affects healthcare utilization and expenditures for comorbid conditions. This study used a U.S. database to compare medical expenditures and health outcomes between adults with comorbidities who have cancer and those without. Methods: This longitudinal analysis utilized the data from the 2008-2014 Medical Expenditure Panel Survey (Household Component). Participants with one or more of 19 chronic health conditions (ICD-9 coded) relevant to primary care were classified based on self-reported cancer history. Outcomes from the second year of each panel (2009-2015) included comorbidity-specific healthcare utilization, medical expenditures, functional status, HRQoL, and health utility. Cost differences conditional on positive expenditures were analyzed using generalized linear models (gamma regression and log-link), while differences in healthcare utilization were examined using negative binomial regression. All models were adjusted for demographic, socioeconomic, and lifestyle covariates. Results: A weighted total of 24,057,137 adults with at least one comorbidity (mean age 58.3±15.8 years; 59% female) were included, of whom 10% (n=2,393,300) reported a history of cancer. Compared with non-cancer patients, cancer patients received more comorbidity-specific home health visits (IRR 2.01, 95% CI 1.13-3.57) but had lower total comorbidity-specific expenditures (OR 0.81, 95% CI 0.71-0.92). Cancer patients also incurred lower comorbidity-specific hospitalization costs and out-of-pocket costs for emergency department (ED) visits (p<0.05). Specifically, they had reduced total expenditures for arthritis (OR 0.60, 95% CI 0.39-0.93) and stomach problems (OR 0.42, 95% CI 0.22-0.81) and reduced out-of-pocket costs for thyroid problems (OR 0.55, 95% CI 0.36-0.86) and osteoporosis (OR 0.41, 95% CI 0.18-0.92). Among multimorbid patients (≥2 conditions; 55.4%), cancer patients incurred lower out-of-pocket costs for ED visits (OR 0.42, 95% CI 0.26-0.68). For health outcomes, cancer patients reported more functional limitations than non-cancer patients in instrumental activities of daily living (10.8% vs 8.5%), role functioning (26.2% vs 20.5%), and cognitive function (13.6% vs 11.2%), all p<0.05. Moreover, multimorbid patients with cancer had lower HRQoL and health utilities (p<0.05). Similar trends were observed for cancer patients with depression, hypertension, chronic lung disease, osteoporosis, and thyroid problems. Conclusions: Cancer patients with comorbidities had greater functional limitations but lower medical expenditures for comorbidity care than non-cancer patients, suggesting inequities in primary care. Healthcare resources should be prioritized for cancer patients with comorbidities and poor functional status.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (5)
Panpan Xiao
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
Bo Wang
Herbert H. Loong
Fahima Dossa, MD, PhD, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA; Chandrajit P. Raut, MD, Department of Surgery, Mass General Brigham, Harvard Medical School, Boston, MA; Andrew J. Wagner, MD, PhD, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Robin L. Jones, MD, Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom; Rebecca A. Gladdy, MD, PhD, Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Abha A. Gupta, MD, Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Kenneth Cardona, MD, Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA; David E. Gyorki, MD, Division of Cancer Surgery, Peter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Au...
Chun-Kit Ngan
Worcester Polytechnic Institute, Worcester, MA
Yin Ting Cheung
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China